Prior to his USC role, Dr. Thomas Lobl was Emerging Technology Strategist at Alfred Mann Foundation. He has a PhD from Johns Hopkins University and post-graduate work at Caltech and Rockefeller University. He has worked in the pharmaceutical industry for 39+ years in both big pharma and biotech start-up companies.
In 2002, he joined the Al Mann family of companies at AlleCure/Mannkind as V.P. and subsequently as Senior V.P. of R&D. In January 2004, he helped to start NeuroSystec and was acting CEO for nearly 7 years. NeuroSystec was developing an anti-tinnitus drug. NeuroSystec has been sold to Otonomy (San Diego). Since October 2011 he has been working at the Alfred Mann Foundation as an Emerging Technology Strategist. He has over 74 publications and patents and has been a scientific reviewer or editorial board member on a variety of scientific journals.
He has been a board member and/or officer of a number of scientific organizations and is currently Chair of the American Tinnitus Association Board of Directors. He is/has been on a number of NIH grant review study sections (currently on: Sensory Technologies). Lobl’s scientific and research experience is quite broad and include medicinal and peptide/protein chemistry, drug discovery and development, clinical development, drug and tissue-specific delivery systems in the cancer, inflammatory, infectious, reproductive and endocrinology diseases areas. He is currently working in the neurobiology area for diseases/injuries of the brain and peripheral nervous system using medical devices and drug delivery systems. He has helped prepare grants/contracts that have brought in several millions of dollars in research support for AMF in areas of implanted myoelectric sensors. His personal research interests is in the development of skull-mounted pumps, sensors and microstimulators for treating brain diseases through tissue-specific drug delivery to areas of the brain responsible for various disorders.